Zenas BioPharma (ZBIO)

• Market cap: $2.1B
• 1 day: -8.1%
• 5 days: 7.99%
• 1 month: 5.34%
• 3 months: 89.84%
• 6 months: 302.99%
• Year to date: 333.41%
• 1 year: 334.37%
• 5 years: 115.15%
• 10 years: 115.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130